“Inevitable is a good word for it. It was just really a matter of time. It was very clear that Novartis, at some point, was going to have to . . . come up with a deal that worked for everybody.“

– Larry Haimovitch, president of Haimovitch Medical Technology Consultants (Mill Valley, California), on the Novartis offer to acquire the remaining 23% of shares of Alcon it did not already own for $12.9 billion,“ pp. 1 , 5.